000176949 001__ 176949
000176949 005__ 20240229133726.0
000176949 0247_ $$2doi$$a10.3390/cancers13184706
000176949 0247_ $$2pmid$$apmid:34572934
000176949 0247_ $$2pmc$$apmc:PMC8472377
000176949 0247_ $$2altmetric$$aaltmetric:114169702
000176949 037__ $$aDKFZ-2021-02189
000176949 041__ $$aEnglish
000176949 082__ $$a610
000176949 1001_ $$00000-0002-4000-6904$$aBaertsch, Marc-Andrea$$b0
000176949 245__ $$aCarfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
000176949 260__ $$aBasel$$bMDPI$$c2021
000176949 3367_ $$2DRIVER$$aarticle
000176949 3367_ $$2DataCite$$aOutput Types/Journal article
000176949 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634042313_10604
000176949 3367_ $$2BibTeX$$aARTICLE
000176949 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000176949 3367_ $$00$$2EndNote$$aJournal Article
000176949 500__ $$a#LA:A360#
000176949 520__ $$aSalvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57%) attained ≥ very good partial response (VGPR), which increased to 34/44 (77%) at best response after salvage HDCT/ASCT. Median progression-free survival (PFS) was 23.3 months from salvage HDCT/ASCT. Patients with ≥ VGPR at the time of salvage HDCT/ASCT and those receiving maintenance treatment post salvage HDCT/ASCT had significantly superior PFS (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009). In patients achieving at least an equal depth of response before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS after salvage HDCT/ASCT was comparable to the frontline situation (p = 0.3). This is the first report of state-of-the-art triplet re-induction and salvage HDCT/ASCT for RRMM after frontline transplantation. Deep remissions achieved with KRd translate into prolonged PFS following salvage HDCT/ASCT and are enhanced by maintenance treatment.
000176949 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000176949 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000176949 650_7 $$2Other$$alenalidomide maintenance
000176949 650_7 $$2Other$$amultiple myeloma
000176949 650_7 $$2Other$$asalvage autologous stem cell transplantation
000176949 650_7 $$2Other$$asalvage high-dose chemotherapy
000176949 7001_ $$aFougereau, Mathilde$$b1
000176949 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000176949 7001_ $$aSauer, Sandra$$b3
000176949 7001_ $$aBreitkreutz, Iris$$b4
000176949 7001_ $$aJordan, Karin$$b5
000176949 7001_ $$aMüller-Tidow, Carsten$$b6
000176949 7001_ $$aGoldschmidt, Hartmut$$b7
000176949 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b8$$udkfz
000176949 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b9
000176949 7001_ $$0P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aGiesen, Nicola$$b10$$eLast author$$udkfz
000176949 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13184706$$gVol. 13, no. 18, p. 4706 -$$n18$$p4706 $$tCancers$$v13$$x2072-6694$$y2021
000176949 909CO $$ooai:inrepo02.dkfz.de:176949$$pVDB
000176949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000176949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000176949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000176949 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000176949 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000176949 9141_ $$y2021
000176949 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000176949 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000176949 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000176949 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000176949 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x1
000176949 980__ $$ajournal
000176949 980__ $$aVDB
000176949 980__ $$aI:(DE-He78)C060-20160331
000176949 980__ $$aI:(DE-He78)A360-20160331
000176949 980__ $$aUNRESTRICTED